Skip to content
My WebMD Sign In, Sign Up

Cervical Cancer Health Center

Font Size
A
A
A

Stage Information for Cervical Cancer

Note: This Stage Information section has been updated to include information from the seventh edition (2010) of the American Joint Committee on Cancer's AJCC Cancer Staging Manual. The PDQ Adult Treatment Editorial Board, which is responsible for maintaining this summary, is currently reviewing the new staging categories to determine whether additional changes need to be made to other parts of the summary. Any necessary changes will be made as soon as possible.

Cervical carcinoma has its origins at the squamous-columnar junction whether in the endocervical canal or on the portion of the cervix. The precursor lesion is dysplasia or carcinoma in situ (cervical intraepithelial neoplasia [CIN]), which can subsequently become invasive cancer. This process can be quite slow. Longitudinal studies have shown that in untreated patients with in situ cervical cancer, 30% to 70% will develop invasive carcinoma over a period of 10 to 12 years. However, in about 10% of patients, lesions can progress from in situ to invasive in a period of less than 1 year. As it becomes invasive, the tumor breaks through the basement membrane and invades the cervical stroma. Extension of the tumor in the cervix may ultimately manifest as ulceration, exophytic tumor, or extensive infiltration of underlying tissue including bladder or rectum.

In addition to local invasion, carcinoma of the cervix can spread via the regional lymphatics or bloodstream. Tumor dissemination is generally a function of the extent and invasiveness of the local lesion. While cancer of the cervix generally progresses in an orderly manner, occasionally a small tumor with distant metastasis is seen. For this reason, patients must be carefully evaluated for metastatic disease.

Pretreatment surgical staging is the most accurate method to determine the extent of disease.[1] Because there is little evidence to demonstrate overall improved survival with routine surgical staging, the staging usually should be performed only as part of a clinical trial. Pretreatment surgical staging in bulky but locally curable disease may be indicated in select cases when a nonsurgical search for metastatic disease is negative. If abnormal nodes are detected by computed tomography scan or lymphangiography, fine-needle aspiration should be negative before a surgical staging procedure is performed.

Definitions of TNM and FIGO

The American Joint Committee on Cancer (AJCC) and the F�deration Internationale de Gyn�cologie et d'Obst�trique (FIGO) have designated staging to define cervical cancer.[2,3] The definitions of the AJCC's T, N, and M categories correspond to the stages accepted by FIGO. Both systems are included for comparison.

Table 1. Primary Tumor (T)a

FIGO = F�deration Internationale de Gyn�cologie et d'Obst�trique.
a Reprinted with permission from AJCC: Cervix uteri. In: Edge SB, Byrd DR, Compton CC, et al., eds.: AJCC Cancer Staging Manual. 7th ed. New York, NY: Springer, 2010, pp 395-402.
b FIGO no longer includes stage 0 (Tis).
c All macroscopically visible lesions-even with superficial invasion-are T1b/IB.
TNM Categories FIGO Stages
TX Primary tumor cannot be assessed.
T0 No evidence of primary tumor.
Tisb Carcinoma in situ (preinvasive carcinoma).
T1 I Cervical carcinoma confined to uterus (extension to corpus should be disregarded).
T1ac IA Invasive carcinoma diagnosed only by microscopy. Stromal invasion with a maximum depth of 5.0 mm measured from the base of the epithelium and a horizontal spread of ?7.0 mm. Vascular space involvement, venous or lymphatic, does not affect classification.
T1a1 IA1 Measured stromal invasion ?3.0 mm in depth and ?7.0 mm in horizontal spread.
T1a2 IA2 Measured stromal invasion >3.0 mm and ?5.0 mm with a horizontal spread of ?7.0 mm.
T1b IB Clinically visible lesion confined to the cervix or microscopic lesion >T1a/IA2.
T1b1 IB1 Clinically visible lesion ?4.0 cm in greatest dimension.
T1b2 IB2 Clinically visible lesion >4.0 cm in greatest dimension.
T2 II Cervical carcinoma invades beyond uterus but not to pelvic wall or to lower third of vagina.
T2a IIA Tumor without parametrial invasion.
T2a1 IIA1 Clinically visible lesion ?4.0 cm in greatest dimension.
T2a2 IIA2 Clinically visible lesion >4.0 cm in greatest dimension.
T2b IIB Tumor with parametrial invasion.
T3 III Tumor extends to pelvic wall and/or involves lower third of vagina, and/or causes hydronephrosis or nonfunctioning kidney.
T3a IIIA Tumor involves lower third of vagina, no extension to pelvic wall.
T3b IIIB Tumor extends to pelvic wall and/or causes hydronephrosis or nonfunctioning kidney.
T4 IVA Tumor invades mucosa of bladder or rectum, and/or extends beyond true pelvis (bullous edema is not sufficient to classify a tumor as T4).
1 | 2 | 3

WebMD Public Information from the National Cancer Institute

Last Updated: May 16, 2012
This information is not intended to replace the advice of a doctor. Healthwise disclaims any liability for the decisions you make based on this information.

Today in Cervical Cancer

15 Cancer Symptoms Women Ignore
FEATURE
Dna Test To Help Diagnose Cervical Cancer
VIDEO
 
cancer fighting foods
SLIDESHOW
Could Green Tea Prevent Cervical Cancer
VIDEO
 
Integrative Medicine Cancer Quiz
QUIZ
Lifestyle Tips for Depression Slideshow
SLIDESHOW
 
Screening Tests for Women
Slideshow
what is your cancer risk
HEALTH CHECK